Skip to main content

Table 4 Pooled results of the meta-analysis of healthcare costs and hospitalization costs by subgroups

From: The health economic impact of disease management programs for COPD: a systematic literature review and meta-analysis

Characteristics

Subgroup*

Healthcare utilization costs

Hospitalization costs

Study (N)

Mean difference (min-max)

Study (N)

Mean difference (min-max)

Intervention

CCM

1-2

3

-428 (-1875 to 1018)

3

-311 (-1667 to 1045)

3+

5

-1047 (-2230 to 137)

3

-1378 (-2609 to -164)

Number of involved healthcare provider disciplines

2-3

4

-1328 (-2554 to -101)

2

-1674 (-3155 to -192)

4+

3

-282 (-2510 to 1945)

3

-610 (-1770 to 550)

Intervention duration (months)

0-12

2

-345 (-1986 to 1296)

2

-156 (-1820 to 1508)

12+

6

-1066 (-2232 to 99)

4

-1406 (-2566 to -246)

Study

Design

RCT

5

-866 (-1550 to -183)

  

Non-RCT

3

-1074 (-2945 to 797)

  

Region

EU

4

-168 (-1043 to 706)

3

-323 (-1405 to 758)

 

Non-EU

4

-1731 (-2507 to -955)

3

-1681 (-3070 to -293)

Quality of study

0-60

3

-872 (-3253 to 1509)

2

806 (-1843 to 3456)

60+

5

-816 (-1543 to -89)

4

-1266 (-2283 to -250)

Patient

Age

0-65

3

-307 (-1195 to 581)

2

-156 (-1820 to 1508)

 

65+

4

-1128 (-2694 to 437)

4

-1406 (-2566 to -246)

% male

0-60

4

-929 (-1829 to -29)

3

-1790 (-3180 to -401)

60+

3

98 (-1568 to 1764)

3

-738 (-1437 to -39)

GOLD

2

4

-168 (-1043 to 706)

3

-323 (-1405 to 758)

 

3+

3

-1558 (-2740 to -375)

3

-1681 (-3070 to -293)

Exacerbation

Yes

2

-1047 (-1633 to -462)

2

-941 (-1474 to -407)

No**

6

-850 (-1626 to -74)

4

-920 (-2441 to 601)

  1. *If subgroup assignment was impossible, the study was excluded in the meta-analyses.
  2. ** Having a history of one or more exacerbations was not stated in the inclusion criteria.
  3. CCM Chronic care model, RCT Randomized control trials, EU European union, GOLD Global initiative for chronic obstructive lung disease.